#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
The World Health Organization (WHO) has updated its assessment on cannabis risks, citing new evidence linking its use to an elevated risk of psychotic episodes, particularly in individuals with a predisposition to mental health disorders. This update underscores the importance for clinicians to consider potential psychiatric complications when assessing and managing patients using cannabis.
🔬 A recent update by the World Health Organization (WHO) highlights a strengthened association between cannabis use and an elevated risk of psychotic episodes, particularly in individuals with a predisposition to mental health disorders. This underscores the complexity of cannabis’s impact on patient health, as factors such as age at first use, frequency, potency, and specific cannabinoid profiles may significantly influence outcomes. In clinical practice, healthcare providers should remain vigilant for signs of psychosis in patients who use cannabis, especially those with a personal or family history of mental illness. This awareness can facilitate early intervention and potentially mitigate the negative consequences associated with cannabis use.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
